Hospital
Alameda Health System
Alameda Health System was paid $172.03M by Medicaid between Jan 2018 and Dec 2024, across 698 billing codes. Its largest line is 0681, — 13% of everything it billed.
33Billing provider infoALAMEDA HEALTH SYSTEM
OAKLAND, CA 94602
OAKLAND, CA 94602
33aNPI1700087590assigned 05/30/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$172.03M
24GClaims4,052,086
24DCodes billed698
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#7 of 410
Median peer was paid$6.90M
This provider vs. median25×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 413,250 | $13.00M | |
| 2019 | 380,927 | $12.24M | |
| 2020 | 399,848 | $15.32M | |
| 2021 | 632,824 | $21.23M | |
| 2022 | 637,687 | $29.95M | |
| 2023 | 763,713 | $37.51M | |
| 2024incomplete | 823,837 | $42.78M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0681 | 13% | 1,342 | 1,332 | $21.63M | |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.5% | 199,909 | 176,316 | $12.94M |
| J9271 | Injection, pembrolizumab, 1 mg | 6.4% | 821 | 569 | $11.01M |
| 99070 | 3.1% | 168,675 | 62,066 | $5.32M | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | 3.0% | 125,763 | 100,646 | $5.16M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 21,107 | 20,704 | $4.60M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 19,371 | 18,924 | $3.61M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.9% | 34,253 | 33,767 | $3.28M |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.5% | 7,495 | 7,363 | $2.61M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 22,658 | 20,458 | $2.33M |
| 99199 | Unlisted special service, procedure or report | 1.3% | 28,256 | 23,973 | $2.32M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 16,192 | 16,061 | $2.20M |
686 more codes
| J3490 | Unclassified drugs | 1.3% | 79,368 | $2.17M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 50,154 | $2.14M |
| 99283 | Emergency room visit (moderate) | 1.2% | 51,423 | $2.03M |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.2% | 4,949 | $2.00M |
| 80053 | Comprehensive metabolic panel | 1.1% | 176,318 | $1.97M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.1% | 2,347 | $1.83M |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 21,090 | $1.65M |
| Z7502 | <1% | 41,250 | $1.53M | |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | <1% | 354 | $1.39M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 17,799 | $1.37M |
| 0450 | Emergency room services | <1% | 20,055 | $1.36M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 10,344 | $1.35M |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 20,954 | $1.31M |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,870 | $1.23M |
| 93308 | <1% | 7,962 | $1.22M | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 17,550 | $1.17M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 152,740 | $1.15M |
| 99221 | <1% | 1,276 | $1.14M | |
| 86480 | <1% | 21,078 | $1.12M | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 13,680 | $1.10M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 33,263 | $1.10M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 33,256 | $1.09M |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 65,491 | $1.06M |
| 0761 | <1% | 23,682 | $1.03M | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,661 | $1.02M |
| 86703 | <1% | 79,862 | $991K | |
| J2182 | Injection, mepolizumab, 1 mg | <1% | 209 | $969K |
| 97139 | <1% | 46,598 | $962K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 41,722 | $941K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 14,616 | $933K |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 522 | $928K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 27,611 | $920K |
| J3357 | Ustekinumab, for subcutaneous injection, 1 mg | <1% | 53 | $865K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 36,567 | $859K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,629 | $802K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 96,152 | $800K |
| 80061 | Lipid panel | <1% | 64,038 | $781K |
| 70486 | <1% | 2,269 | $757K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 11,879 | $754K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 14,282 | $739K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 37,941 | $735K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 14,534 | $717K |
| 86803 | <1% | 53,017 | $699K | |
| 72141 | <1% | 1,024 | $698K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 27,218 | $682K |
| 71250 | <1% | 2,037 | $678K | |
| 71045 | Radiologic examination, chest; single view | <1% | 62,936 | $633K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15,823 | $609K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 9,745 | $583K |
| 76830 | Ultrasound, transvaginal | <1% | 9,262 | $564K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,762 | $544K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 3,039 | $530K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 9,549 | $526K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,558 | $504K |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 317 | $501K |
| 85027 | <1% | 69,876 | $463K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,266 | $460K |
| 87490 | <1% | 23,091 | $455K | |
| 86900 | <1% | 13,643 | $431K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 73,784 | $423K |
| 72131 | <1% | 1,058 | $418K | |
| 70498 | <1% | 1,382 | $417K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 10,451 | $413K |
| 77066 | Tomosynthesis, mammo | <1% | 3,539 | $407K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 12,836 | $396K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 13,384 | $390K |
| 70496 | <1% | 1,435 | $390K | |
| 93970 | <1% | 3,753 | $382K | |
| 87590 | <1% | 23,087 | $374K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 4,821 | $368K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,092 | $363K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 19,199 | $359K |
| 76642 | <1% | 6,080 | $345K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 3,668 | $327K |
| 97799 | <1% | 17,371 | $323K | |
| 93971 | <1% | 3,945 | $317K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 19,094 | $307K |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | <1% | 244 | $307K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 36,969 | $307K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 3,905 | $307K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 12,879 | $305K |
| 73630 | <1% | 13,222 | $304K | |
| 74178 | <1% | 917 | $301K | |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 5,159 | $299K |
| 76770 | <1% | 3,595 | $297K | |
| 97750 | <1% | 7,845 | $295K | |
| 81329 | <1% | 2,508 | $292K | |
| 73030 | <1% | 11,061 | $275K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 953 | $268K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 780 | $261K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 4,281 | $260K |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 1,405 | $257K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,123 | $255K |
| 76775 | <1% | 3,019 | $255K | |
| 73610 | <1% | 10,733 | $251K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,689 | $248K |
| 87536 | <1% | 3,093 | $239K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,924 | $232K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 542 | $232K |
| 99223 | Prolong inpt eval add15 m | <1% | 2,228 | $227K |
| 73562 | <1% | 9,024 | $225K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,739 | $221K |
| 84484 | <1% | 22,508 | $219K | |
| 84439 | <1% | 25,014 | $215K | |
| 76604 | <1% | 2,850 | $209K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,806 | $207K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 3,435 | $203K |
| 87088 | <1% | 33,671 | $201K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 54 | $200K |
| 73130 | <1% | 8,543 | $199K | |
| 83690 | <1% | 29,951 | $196K | |
| 96415 | <1% | 3,801 | $192K | |
| 82274 | <1% | 13,246 | $192K | |
| 90750 | <1% | 925 | $188K | |
| 90715 | <1% | 4,512 | $188K | |
| D7210 | Extraction, erupted tooth requiring removal of bone and/or sectioning of tooth | <1% | 1,707 | $187K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,331 | $186K |
| D9430 | <1% | 5,899 | $186K | |
| 72128 | <1% | 388 | $184K | |
| 88307 | <1% | 3,708 | $178K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 10,003 | $177K |
| 59025 | Fetal non-stress test | <1% | 5,562 | $177K |
| 82728 | <1% | 14,903 | $175K | |
| Z7610 | <1% | 31,290 | $171K | |
| 87341 | <1% | 18,939 | $171K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,565 | $169K |
| D0330 | Panoramic radiographic image | <1% | 6,100 | $166K |
| 77062 | <1% | 513 | $166K | |
| 96417 | <1% | 3,438 | $161K | |
| 93017 | <1% | 1,875 | $160K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 9,479 | $154K |
| 86780 | <1% | 11,856 | $153K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 5,011 | $152K |
| 77065 | Tomosynthesis, mammo | <1% | 1,776 | $150K |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 259 | $149K |
| 91200 | <1% | 5,545 | $145K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,437 | $144K |
| 73110 | <1% | 5,786 | $144K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16,096 | $144K |
| 73700 | <1% | 363 | $142K | |
| 90686 | <1% | 7,071 | $141K | |
| 84153 | <1% | 7,520 | $138K | |
| 94060 | <1% | 1,725 | $138K | |
| 90837 | Psychotherapy session, about an hour | <1% | 893 | $137K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,858 | $137K |
| Z7500 | <1% | 3,990 | $136K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 198 | $134K |
| 73221 | <1% | 417 | $133K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 4,382 | $132K |
| 82607 | <1% | 11,607 | $132K | |
| 83605 | <1% | 9,261 | $131K | |
| 82043 | <1% | 22,909 | $130K | |
| 86704 | <1% | 10,583 | $129K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,486 | $129K |
| 70491 | <1% | 380 | $128K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 15,488 | $128K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,086 | $128K |
| 81003 | <1% | 70,089 | $127K | |
| 72100 | <1% | 4,095 | $125K | |
| 73502 | <1% | 2,983 | $124K | |
| 99451 | <1% | 3,575 | $121K | |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 8,467 | $119K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,171 | $117K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 4,609 | $116K |
| 0002A | <1% | 2,822 | $112K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 1,748 | $112K |
| 87522 | Neg quan hep c or qual rna | <1% | 2,488 | $111K |
| 83970 | <1% | 3,252 | $110K | |
| 86850 | <1% | 13,564 | $109K | |
| 76536 | <1% | 1,434 | $109K | |
| 73560 | <1% | 4,585 | $108K | |
| 93350 | <1% | 1,108 | $108K | |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | <1% | 408 | $108K |
| 87480 | <1% | 6,010 | $107K | |
| 82746 | <1% | 7,504 | $107K | |
| 93226 | <1% | 1,426 | $106K | |
| 87510 | <1% | 6,010 | $106K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 1,095 | $105K |
| 81025 | <1% | 30,508 | $105K | |
| J1950 | Injection, leuprolide acetate (for depot suspension), per 3.75 mg | <1% | 126 | $104K |
| 83880 | <1% | 3,546 | $104K | |
| 87660 | <1% | 5,972 | $102K | |
| 73590 | <1% | 4,148 | $102K | |
| 73564 | <1% | 2,736 | $101K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,912 | $100K |
| 83735 | <1% | 15,623 | $100K | |
| 96367 | <1% | 1,863 | $98K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,353 | $97K |
| 86762 | <1% | 6,991 | $94K | |
| 71271 | <1% | 751 | $94K | |
| 0001A | <1% | 2,338 | $92K | |
| 86003 | <1% | 1,001 | $92K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 1,376 | $91K |
| 94729 | <1% | 1,473 | $91K | |
| 85610 | <1% | 19,262 | $90K | |
| 74183 | <1% | 263 | $89K | |
| 87517 | <1% | 2,189 | $88K | |
| 86706 | <1% | 14,810 | $88K | |
| 94726 | <1% | 1,294 | $87K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 2,755 | $86K |
| 84702 | <1% | 7,917 | $85K | |
| 82105 | <1% | 4,454 | $85K | |
| 81001 | <1% | 27,300 | $84K | |
| 84466 | <1% | 8,184 | $83K | |
| 0250 | <1% | 4,536 | $83K | |
| 87340 | <1% | 7,713 | $81K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 14,571 | $81K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,742 | $78K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,655 | $78K |
| 93225 | <1% | 1,276 | $76K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,043 | $75K |
| 84460 | <1% | 14,904 | $75K | |
| 77061 | <1% | 303 | $74K | |
| 72170 | <1% | 2,704 | $70K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,467 | $68K |
| 72197 | <1% | 190 | $68K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 154 | $67K |
| 82962 | <1% | 19,843 | $67K | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 1,294 | $66K |
| 86787 | <1% | 6,887 | $65K | |
| 87338 | <1% | 5,547 | $65K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 559 | $65K |
| 88342 | <1% | 2,319 | $64K | |
| 73080 | <1% | 1,743 | $63K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 803 | $63K |
| 86901 | <1% | 13,643 | $62K | |
| 81223 | <1% | 50 | $62K | |
| 87186 | <1% | 9,236 | $62K | |
| 80074 | <1% | 1,368 | $61K | |
| 99460 | <1% | 966 | $61K | |
| 74170 | <1% | 179 | $61K | |
| 86140 | <1% | 12,362 | $61K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 174 | $61K |
| 92553 | <1% | 1,525 | $60K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 250 | $60K |
| 84450 | <1% | 12,243 | $59K | |
| 86682 | <1% | 2,432 | $58K | |
| 83020 | <1% | 4,572 | $57K | |
| 82570 | <1% | 11,654 | $57K | |
| 73552 | <1% | 1,613 | $56K | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 1,238 | $54K |
| 76870 | <1% | 660 | $54K | |
| 59409 | Vaginal delivery only (with or without episiotomy and/or forceps) | <1% | 103 | $54K |
| 86708 | <1% | 4,283 | $54K | |
| 83540 | <1% | 8,929 | $54K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,173 | $53K |
| 87040 | <1% | 3,257 | $52K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,579 | $51K |
| 87070 | <1% | 6,210 | $51K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 1,094 | $51K |
| 76000 | <1% | 3,437 | $51K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 1,092 | $49K |
| 86361 | <1% | 2,515 | $49K | |
| 72040 | <1% | 1,375 | $48K | |
| 83013 | <1% | 869 | $48K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 526 | $46K |
| 31231 | <1% | 841 | $45K | |
| 74174 | <1% | 124 | $45K | |
| 99254 | <1% | 492 | $45K | |
| 73090 | <1% | 1,422 | $45K | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 298 | $45K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 63 | $45K |
| 86038 | <1% | 3,939 | $44K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,503 | $44K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 442 | $44K |
| 83921 | <1% | 2,911 | $43K | |
| 92557 | <1% | 391 | $43K | |
| 96411 | <1% | 1,584 | $42K | |
| 91322 | <1% | 379 | $42K | |
| 87529 | <1% | 717 | $42K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,377 | $42K |
| 93922 | <1% | 1,087 | $41K | |
| 88341 | <1% | 1,408 | $41K | |
| 94618 | <1% | 737 | $41K | |
| 82947 | <1% | 10,419 | $41K | |
| D7230 | <1% | 230 | $41K | |
| 86705 | <1% | 3,091 | $40K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 680 | $40K |
| 87625 | <1% | 1,190 | $40K | |
| 85730 | <1% | 6,804 | $40K | |
| 80179 | <1% | 1,616 | $40K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 214 | $39K |
| 92567 | <1% | 975 | $39K | |
| 93247 | <1% | 319 | $39K | |
| 80143 | <1% | 1,673 | $39K | |
| 86765 | <1% | 2,787 | $39K | |
| 86160 | <1% | 1,978 | $38K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,388 | $38K |
| 85652 | <1% | 14,877 | $37K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,077 | $37K |
| 80076 | <1% | 4,961 | $36K | |
| 82950 | <1% | 6,624 | $36K | |
| 84156 | <1% | 10,967 | $36K | |
| 90670 | <1% | 775 | $36K | |
| 83655 | <1% | 8,272 | $35K | |
| 82565 | <1% | 6,910 | $35K | |
| 73120 | <1% | 917 | $34K | |
| 74018 | <1% | 2,418 | $34K | |
| 82803 | <1% | 1,177 | $34K | |
| 99255 | <1% | 286 | $34K | |
| D9220 | <1% | 160 | $34K | |
| 80069 | <1% | 3,962 | $34K | |
| 90746 | <1% | 558 | $33K | |
| D9223 | Deep sedation/general anesthesia - each subsequent 15 minute increment | <1% | 249 | $33K |
| 87077 | <1% | 4,913 | $33K | |
| 82550 | <1% | 4,961 | $33K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,100 | $33K |
| 73060 | <1% | 939 | $32K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 273 | $32K |
| 31575 | <1% | 602 | $32K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,861 | $32K |
| 84550 | <1% | 7,507 | $32K | |
| 88304 | <1% | 2,111 | $32K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,181 | $31K |
| 87177 | <1% | 4,275 | $31K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 262 | $31K |
| 0004A | <1% | 764 | $30K | |
| 73620 | <1% | 1,016 | $30K | |
| 87634 | <1% | 472 | $30K | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 130 | $30K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,275 | $30K |
| 86735 | <1% | 1,965 | $29K | |
| 96368 | <1% | 1,061 | $29K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,480 | $29K |
| 90732 | <1% | 414 | $29K | |
| 99464 | <1% | 409 | $28K | |
| 52000 | <1% | 288 | $27K | |
| 95812 | <1% | 534 | $27K | |
| 82784 | <1% | 2,432 | $27K | |
| 59425 | <1% | 414 | $26K | |
| 72050 | <1% | 446 | $26K | |
| 86235 | <1% | 1,032 | $26K | |
| 82670 | <1% | 1,100 | $25K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 1,464 | $25K |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 442 | $25K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,367 | $25K |
| 72158 | <1% | 24 | $24K | |
| 86225 | <1% | 2,055 | $24K | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 3,317 | $24K |
| 72110 | <1% | 411 | $24K | |
| 73140 | <1% | 1,100 | $24K | |
| 86141 | <1% | 2,111 | $24K | |
| 87081 | <1% | 3,979 | $24K | |
| 84100 | <1% | 5,731 | $23K | |
| 99218 | <1% | 95 | $23K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 316 | $22K |
| 85379 | <1% | 2,347 | $22K | |
| 99152 | <1% | 628 | $22K | |
| 90677 | <1% | 610 | $22K | |
| 82378 | <1% | 1,108 | $22K | |
| 86359 | <1% | 582 | $22K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,064 | $22K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,619 | $22K |
| 88142 | <1% | 1,145 | $22K | |
| 87209 | <1% | 4,266 | $22K | |
| 90636 | <1% | 197 | $21K | |
| E0114 | Crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips | <1% | 398 | $21K |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 404 | $21K |
| 82040 | <1% | 4,995 | $21K | |
| 83521 | <1% | 670 | $21K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 259 | $20K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 604 | $20K |
| 86334 | <1% | 991 | $20K | |
| 94760 | <1% | 1,495 | $20K | |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | <1% | 27 | $19K |
| 71020 | <1% | 602 | $19K | |
| 83525 | <1% | 1,925 | $19K | |
| D9222 | <1% | 188 | $19K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,914 | $19K |
| 86593 | <1% | 3,983 | $18K | |
| 92134 | <1% | 553 | $18K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 473 | $18K |
| 83721 | <1% | 2,018 | $17K | |
| D7240 | Removal of impacted tooth - completely bony | <1% | 75 | $17K |
| 84425 | <1% | 867 | $17K | |
| 90651 | <1% | 528 | $17K | |
| 84165 | <1% | 1,818 | $17K | |
| 82785 | <1% | 1,331 | $17K | |
| 76801 | <1% | 234 | $17K | |
| 81002 | <1% | 7,420 | $16K | |
| 99243 | <1% | 209 | $16K | |
| 0270 | <1% | 4,446 | $16K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,073 | $16K |
| 87427 | <1% | 863 | $15K | |
| 73600 | <1% | 383 | $15K | |
| 87902 | <1% | 96 | $15K | |
| 83001 | <1% | 1,865 | $15K | |
| 99462 | <1% | 522 | $15K | |
| 0914 | <1% | 379 | $15K | |
| 82247 | <1% | 2,906 | $15K | |
| D9221 | <1% | 152 | $15K | |
| 85007 | <1% | 4,392 | $14K | |
| 83615 | <1% | 2,497 | $14K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 90 | $14K |
| 82627 | <1% | 705 | $14K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 94 | $14K |
| 83516 | <1% | 1,493 | $14K | |
| 92083 | <1% | 294 | $14K | |
| 76882 | <1% | 811 | $13K | |
| 82310 | <1% | 2,525 | $13K | |
| 84481 | <1% | 1,089 | $13K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,168 | $13K |
| 86592 | <1% | 3,057 | $13K | |
| 86200 | <1% | 1,772 | $13K | |
| 92568 | <1% | 748 | $12K | |
| G9012 | Other specified case management service not elsewhere classified | <1% | 10,805 | $12K |
| 84520 | <1% | 2,978 | $12K | |
| 0054A | <1% | 300 | $12K | |
| 87147 | <1% | 1,821 | $12K | |
| 82533 | <1% | 1,473 | $12K | |
| 84403 | <1% | 1,179 | $11K | |
| 73070 | <1% | 249 | $11K | |
| 72070 | <1% | 260 | $11K | |
| 84075 | <1% | 2,146 | $11K | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 214 | $11K |
| 93925 | <1% | 155 | $11K | |
| 82248 | <1% | 2,287 | $11K | |
| 84295 | <1% | 2,211 | $11K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,356 | $11K |
| 73100 | <1% | 252 | $10K | |
| 83550 | <1% | 1,437 | $10K | |
| 97803 | <1% | 308 | $10K | |
| 96376 | <1% | 529 | $10K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,480 | $10K |
| 90656 | <1% | 605 | $10K | |
| 90707 | <1% | 519 | $10K | |
| 87045 | <1% | 1,120 | $10K | |
| 86146 | <1% | 281 | $10K | |
| 90658 | <1% | 472 | $9K | |
| 97802 | <1% | 156 | $9K | |
| H1003 | Prenatal care, at-risk enhanced service; education | <1% | 620 | $9K |
| 84155 | <1% | 2,904 | $9K | |
| 90688 | <1% | 1,160 | $9K | |
| 86147 | <1% | 339 | $9K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 963 | $9K |
| 99156 | <1% | 102 | $9K | |
| 96158 | <1% | 195 | $9K | |
| 87210 | <1% | 2,149 | $8K | |
| 86709 | <1% | 752 | $8K | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 1,913 | $8K |
| 83520 | <1% | 449 | $8K | |
| 90716 | <1% | 461 | $8K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 696 | $8K |
| 99236 | Prolong inpt eval add15 m | <1% | 52 | $8K |
| 93289 | <1% | 247 | $7K | |
| 83090 | <1% | 475 | $7K | |
| 80177 | <1% | 601 | $7K | |
| 86364 | <1% | 569 | $7K | |
| 85045 | <1% | 1,800 | $7K | |
| 82375 | <1% | 517 | $7K | |
| 87205 | <1% | 1,752 | $7K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 588 | $7K |
| 83498 | <1% | 278 | $7K | |
| 92551 | <1% | 619 | $7K | |
| 85018 | <1% | 3,005 | $6K | |
| 84402 | <1% | 257 | $6K | |
| 82652 | <1% | 202 | $6K | |
| 86376 | <1% | 639 | $6K | |
| 82374 | <1% | 1,993 | $6K | |
| 84146 | <1% | 1,692 | $6K | |
| E0100 | Cane, includes canes of all materials, adjustable or fixed, with tip | <1% | 229 | $6K |
| 83993 | <1% | 333 | $6K | |
| 0052A | <1% | 144 | $6K | |
| 83002 | <1% | 707 | $6K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 119 | $6K |
| 84166 | <1% | 350 | $6K | |
| 0003A | <1% | 138 | $6K | |
| 84132 | <1% | 1,495 | $5K | |
| 20610 | <1% | 247 | $5K | |
| 82435 | <1% | 1,275 | $5K | |
| 86255 | <1% | 451 | $5K | |
| 96402 | <1% | 252 | $5K | |
| 93880 | <1% | 111 | $5K | |
| 86431 | <1% | 2,500 | $5K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 341 | $5K |
| 01967 | Neuraxial labor analgesia/anesthesia for planned vaginal delivery | <1% | 112 | $5K |
| 90647 | <1% | 830 | $5K | |
| 93018 | <1% | 388 | $5K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 362 | $5K |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 251 | $5K |
| 90723 | <1% | 766 | $5K | |
| 90633 | <1% | 882 | $5K | |
| 51798 | <1% | 653 | $5K | |
| 93351 | <1% | 14 | $5K | |
| 90680 | <1% | 722 | $5K | |
| 98960 | <1% | 100 | $5K | |
| 95816 | <1% | 76 | $5K | |
| 87400 | <1% | 375 | $5K | |
| G0202 | Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (cad) when performed | <1% | 54 | $4K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 45 | $4K |
| 90734 | <1% | 257 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 62 | $4K |
| 82024 | <1% | 122 | $4K | |
| 00731 | <1% | 40 | $4K | |
| 82397 | <1% | 298 | $4K | |
| 80197 | <1% | 324 | $4K | |
| 87449 | <1% | 242 | $4K | |
| 84630 | <1% | 394 | $4K | |
| V2632 | Posterior chamber intraocular lens | <1% | 14 | $4K |
| 90697 | <1% | 428 | $4K | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 211 | $4K |
| D1110 | Prophylaxis - adult | <1% | 54 | $4K |
| 0360 | <1% | 25 | $4K | |
| 92025 | <1% | 107 | $4K | |
| 92136 | <1% | 76 | $4K | |
| 96401 | <1% | 204 | $4K | |
| G9920 | Screening performed and negative | <1% | 121 | $4K |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 230 | $4K |
| 99157 | <1% | 29 | $4K | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | <1% | 248 | $4K |
| 90480 | <1% | 173 | $3K | |
| 11721 | <1% | 182 | $3K | |
| 93248 | <1% | 155 | $3K | |
| 82010 | <1% | 454 | $3K | |
| 86015 | <1% | 293 | $3K | |
| 84445 | <1% | 274 | $3K | |
| 87329 | <1% | 200 | $3K | |
| 92229 | <1% | 58 | $3K | |
| 82977 | <1% | 1,261 | $3K | |
| 82088 | <1% | 93 | $3K | |
| 83519 | <1% | 229 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 238 | $3K |
| 86800 | <1% | 354 | $3K | |
| 93975 | <1% | 73 | $3K | |
| 92522 | <1% | 52 | $3K | |
| 78306 | <1% | 26 | $3K | |
| 84145 | <1% | 136 | $3K | |
| 93016 | <1% | 129 | $3K | |
| 87206 | <1% | 498 | $3K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 174 | $3K |
| 82390 | <1% | 313 | $3K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 12 | $3K |
| 96156 | <1% | 245 | $3K | |
| 81401 | <1% | 17 | $3K | |
| 99245 | <1% | 17 | $3K | |
| 0051A | <1% | 69 | $3K | |
| 73000 | <1% | 97 | $3K | |
| 31500 | <1% | 44 | $3K | |
| 92133 | <1% | 99 | $3K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 225 | $3K |
| 0760 | <1% | 58 | $3K | |
| 87592 | <1% | 56 | $3K | |
| 84590 | <1% | 249 | $3K | |
| 99417 | Prolong home eval add 15m | <1% | 73 | $3K |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 94 | $3K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 101 | $3K |
| 95717 | <1% | 25 | $2K | |
| G0204 | Diagnostic mammography, including computer-aided detection (cad) when performed; bilateral | <1% | 24 | $2K |
| 84681 | <1% | 159 | $2K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 71 | $2K |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 12 | $2K |
| 82525 | <1% | 210 | $2K | |
| 85613 | <1% | 230 | $2K | |
| 91318 | <1% | 184 | $2K | |
| 82542 | <1% | 120 | $2K | |
| 82103 | <1% | 169 | $2K | |
| 95070 | <1% | 20 | $2K | |
| 84244 | <1% | 101 | $2K | |
| 91319 | <1% | 83 | $2K | |
| 72082 | <1% | 27 | $2K | |
| 82166 | <1% | 181 | $2K | |
| 00813 | <1% | 12 | $2K | |
| 93227 | <1% | 97 | $2K | |
| 0510 | <1% | 557 | $2K | |
| X3908 | <1% | 56 | $2K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 67 | $2K |
| 73200 | <1% | 12 | $2K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 33 | $2K |
| 87046 | <1% | 638 | $2K | |
| 82610 | <1% | 110 | $2K | |
| D0274 | Bitewings - four radiographic images | <1% | 75 | $2K |
| 87350 | <1% | 155 | $2K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 212 | $2K |
| 87116 | <1% | 142 | $2K | |
| 87324 | <1% | 162 | $2K | |
| 90700 | <1% | 300 | $1K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 19 | $1K |
| 76857 | <1% | 26 | $1K | |
| 86304 | <1% | 140 | $1K | |
| 93356 | <1% | 118 | $1K | |
| 99401 | <1% | 118 | $1K | |
| 84703 | <1% | 280 | $1K | |
| 95718 | <1% | 12 | $1K | |
| 82330 | <1% | 109 | $1K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 527 | $1K |
| 82140 | <1% | 91 | $1K | |
| 90685 | <1% | 197 | $1K | |
| 95813 | <1% | 15 | $1K | |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 95 | $1K |
| 97018 | <1% | 87 | $1K | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 37 | $1K |
| 76813 | <1% | 15 | $1K | |
| 99253 | <1% | 12 | $1K | |
| 96409 | <1% | 40 | $1K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 91 | $1K |
| 84154 | <1% | 75 | $1K | |
| 94375 | <1% | 19 | $1K | |
| 99241 | <1% | 27 | $1K | |
| 80164 | <1% | 79 | $1K | |
| 77080 | <1% | 104 | $1K | |
| 96523 | <1% | 28 | $1K | |
| 71010 | <1% | 50 | $1K | |
| D0270 | <1% | 204 | $1K | |
| 86340 | <1% | 68 | $994.73 | |
| 82150 | <1% | 168 | $987.98 | |
| 99252 | <1% | 29 | $987.81 | |
| 86021 | <1% | 70 | $978.85 | |
| 72190 | <1% | 25 | $974.36 | |
| 88173 | <1% | 13 | $949.05 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 146 | $945.71 |
| 93288 | <1% | 36 | $927.46 | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 13 | $914.42 |
| 84300 | <1% | 200 | $896.92 | |
| 71101 | <1% | 14 | $879.07 | |
| 73660 | <1% | 41 | $874.55 | |
| 94200 | <1% | 23 | $874.50 | |
| 85014 | <1% | 389 | $874.02 | |
| 51705 | <1% | 31 | $861.19 | |
| 91320 | <1% | 58 | $812.00 | |
| 97032 | <1% | 32 | $784.21 | |
| 82465 | <1% | 188 | $758.07 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 35 | $757.10 |
| 84480 | <1% | 250 | $750.88 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 78 | $713.52 |
| 74220 | <1% | 12 | $711.96 | |
| 99188 | <1% | 35 | $693.00 | |
| 90710 | <1% | 208 | $675.00 | |
| 88720 | <1% | 186 | $658.34 | |
| 85060 | <1% | 56 | $644.13 | |
| 86301 | <1% | 52 | $613.02 | |
| D0210 | Intraoral - complete series of radiographic images | <1% | 14 | $612.00 |
| 51701 | <1% | 30 | $587.25 | |
| 90714 | <1% | 43 | $553.36 | |
| 86812 | <1% | 25 | $544.00 | |
| G9008 | Coordinated care fee, physician coordinated care oversight services | <1% | 14,692 | $542.92 |
| 86036 | <1% | 69 | $541.52 | |
| 87109 | <1% | 39 | $533.52 | |
| 84144 | <1% | 35 | $516.25 | |
| 94644 | <1% | 14 | $499.52 | |
| 0720 | <1% | 13 | $497.61 | |
| 81015 | <1% | 216 | $486.13 | |
| 92504 | <1% | 31 | $471.74 | |
| 87101 | <1% | 64 | $452.10 | |
| 87255 | <1% | 28 | $441.38 | |
| 90696 | <1% | 120 | $420.00 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 92 | $408.42 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 27 | $400.99 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 298 | $379.81 |
| 97035 | <1% | 42 | $373.28 | |
| 88112 | <1% | 24 | $343.75 | |
| 84207 | <1% | 15 | $334.88 | |
| 10060 | <1% | 26 | $329.24 | |
| 73565 | <1% | 13 | $309.20 | |
| 90619 | <1% | 30 | $300.00 | |
| 86300 | <1% | 15 | $292.86 | |
| 96159 | <1% | 22 | $261.43 | |
| 84305 | <1% | 12 | $232.56 | |
| 86039 | <1% | 39 | $231.66 | |
| 84270 | <1% | 18 | $225.72 | |
| 92015 | Determination of refractive state | <1% | 27 | $216.27 |
| 99173 | <1% | 143 | $183.84 | |
| 83835 | <1% | 12 | $180.72 | |
| 76942 | <1% | 18 | $180.24 | |
| 82164 | <1% | 13 | $168.74 | |
| 82085 | <1% | 25 | $161.52 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 495 | $144.56 |
| 11043 | <1% | 18 | $138.30 | |
| 86317 | <1% | 28 | $133.00 | |
| 97161 | <1% | 516 | $130.61 | |
| 82985 | <1% | 122 | $86.62 | |
| 88300 | <1% | 26 | $83.14 | |
| 84432 | <1% | 13 | $75.14 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 161 | $71.50 |
| Q0164 | Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 18 | $60.97 |
| 84133 | <1% | 12 | $53.94 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 96 | $40.76 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 79 | $32.78 |
| 86308 | <1% | 12 | $29.88 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 50 | $16.00 |
| D9995 | <1% | 54 | $12.96 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 113 | $1.83 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 13 | $0.22 |
| D0160 | 0% | 218 | $0.00 | |
| 0516 | 0% | 15 | $0.00 | |
| D0140 | Limited oral evaluation - problem focused | 0% | 613 | $0.00 |
| 99443 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFLEEKS, BRENDA (DIRECTOR, PFS)
| Provider | Location | Paid |
|---|---|---|
| Alameda Health System | Oakland, CA | $5.58M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.